GLP 1s and the Unintended Consequences of the $100 Billion Market
- Author
- Life Science Networks
- Published
- Thu 07 Nov 2024
- Episode Link
- https://podcasters.spotify.com/pod/show/life-science-networks/episodes/GLP-1s-and-the-Unintended-Consequences-of-the-100-Billion-Market-e2qmcio
GLP-1 drugs have become a game-changer in treating obesity and type 2 diabetes, forecast to reach a $100 billion market value by 2029.
However, their rapid rise raises important questions about resource allocation in pharmaceutical development and manufacturing, as well as affecting the dynamics between patients, healthcare providers, and biopharma.
In the latest episode of the PharmaSource podcast, Ben Locwin, Chief Scientist at Black Diamond Networks, explains that GLP-1 drugs represent a significant breakthrough in the treatment of obesity and diabetes and the unintended consequences they are bringing to the industry.
